Open an account

Cytek Biosciences

CTKB · NASDAQ

$5.34+$0.09 (+1.71%)TodayMarket closed ·
Prev close $5.25

About CTKB

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 702 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Employees
702
Headquarters
Fremont, California
Listed
Jul 23, 2021
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
cytekbio.com

CTKB key statistics

Market cap
694.11M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.58M
Volume
805.79K
Open price
$5.29
High today
$5.49
Low today
$5.26
52 Week high
$6.21
52 Week low
$3.31

Cytek Biosciences (CTKB) at a glance

As of Oct 20, 2026, Cytek Biosciences (CTKB) shares are priced at $5.34, giving the company a market cap of 694.11M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.26 and $5.49. The current price is 1.5% above the day's low and 2.7% below its high.

Volume so far is 805.79K shares, below the average of 1.58M shares a day.

Over the past year Cytek Biosciences has ranged from $3.31 to $6.21, and now sits 70% of the way up that range.

Cytek Biosciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.0867.

The average analyst price target is $5.67, 6.2% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 4 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 6 analystsAvg $5.67
Low
$4.80
Now
$5.34
High
$7.88

CTKB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 54.9% on average.

  1. Q3 FY24: reported $0.01 per share against an estimate of -$0.0153
  2. Q4 FY24: reported $0.07 per share against an estimate of $0.053
  3. Q1 FY25: reported -$0.09 per share against an estimate of -$0.0459
  4. Q2 FY25: reported -$0.04 per share against an estimate of -$0.0714
  5. Q3 FY25: reported -$0.04 per share against an estimate of -$0.0536
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.0204
  7. Q1 FY26: reported -$0.15 per share against an estimate of -$0.0986
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.0867

CTKB news

  • Press releaseGlobe Newswire

    Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool

  • Press releaseGlobe Newswire

    Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

  • Press releaseGlobe Newswire

    Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

  • Press releaseGlobe Newswire

    Cytek Biosciences to Participate in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding

  • Press releaseGlobe Newswire

    Cytek Biosciences Reports Second Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026

  • Press releaseGlobe Newswire

    Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement

Similar companies

Companies in the same industry as Cytek Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.